A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/Tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis

Trial Profile

A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/Tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Gram-negative infections
  • Focus Pharmacokinetics
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2017 Status changed from recruiting to completed.
    • 28 Jul 2017 Status changed from recruiting to completed.
    • 19 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top